3455 studies found for:    "Carcinoma, Non-Small-Cell Lung"
Show Display Options
Rank Status Study
21 Completed A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small Cell-Lung;   Lung Neoplasms;   Lung Cancer;   Respiratory Tract Neoplasms
Interventions: Biological: AV-299 + gefitinib;   Drug: Gefitinib
22 Active, not recruiting Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Lenalidomide
23 Active, not recruiting Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non Small Cell Lung
Interventions: Drug: Docetaxel;   Drug: Suramin
24 Withdrawn Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell-Lung
Intervention: Drug: Temoporfin
25 Completed
Has Results
Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Gefitinib retreatment
26 Completed Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Sym004 plus Platinum-Doublet Chemotherapy
27 Completed
Has Results
Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-small Cell Lung
Intervention: Drug: Tarceva (Erlotinib)
28 Completed Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: neoadjuvant erlotinib therapy;   Drug: neoadjuvant gemcitabine/carboplatin therapy
29 Recruiting Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Conditions: Carcinoma, Non-Small Cell Lung;   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer
Intervention: Drug: Pazopanib
30 Completed Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SGN-15;   Drug: Docetaxel
31 Withdrawn TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Bevacizumab
32 Terminated Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Tecemotide;   Drug: Placebo;   Drug: Cyclophosphamide (CPA);   Drug: Saline (sodium chloride)
33 Not yet recruiting Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
Conditions: Non-small Cell Lung Cancer;   Metastatic Non-small Cell Lung Cancer;   Radiotherapy;   Thymalfasin
Interventions: Radiation: Radiotherapy;   Drug: Thymalfasin
34 Recruiting Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Oshadi D and Oshadi R;   Drug: Docetaxel
35 Recruiting Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: JNJ-64041757 (Cohort 1A and 1B);   Biological: JNJ-64041757 (Cohort 2A and 2B)
36 Completed Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: MVA-MUC1-IL2;   Drug: 1st line Chemotherapy
37 Completed
Has Results
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Conditions: Carcinoma, Non-Small-Cell Lung;   Lung Neoplasms
Interventions: Biological: Tecemotide (L-BLP25);   Drug: Single low dose cyclophosphamide;   Other: Best standard of care (BSC)
38 Completed ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: ALIMTA;   Drug: Carboplatin
39 Terminated
Has Results
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Vorinostat;   Drug: erlotinib
40 Completed A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: LY900003

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years